Feline Hyperthyroidism Masking Concurrent CKD: A Diagnostic Problem

Treating hyperthyroidism in cats sometimes unmasks underlying kidney disease. This is not a rare edge case. It happens in roughly 40% of hyperthyroid cats over 10 years old, and when it does, the clinical picture shifts from a manageable chronic condition to an acute decompensation that feels unexpected — even though the data to predict it was available before treatment started.

The mechanism is well-established. Hyperthyroidism elevates cardiac output and increases renal blood flow, producing a GFR that appears normal or even high by standard chemistry markers. The kidneys are functioning above their actual capacity, maintained by the thyroid-driven hyperperfusion. When methimazole or radioiodine treatment brings thyroid hormone levels down, cardiac output decreases, renal perfusion drops to baseline, and the true GFR is revealed — which in 40% of cats is below the threshold for CKD diagnosis.

The Clinical Stakes

Understanding the stakes matters before getting into detection. A cat treated for hyperthyroidism without pre-treatment renal assessment faces two possible bad outcomes:

1. Untreated CKD remains undetected: If the clinician does not recheck renal values after initiating treatment, the concurrent CKD goes unmanaged until it becomes symptomatic — often Stage 3 or 4 before the owner notices weight loss and polyuria.
2. Suboptimal hyperthyroidism management: In cats with known concurrent CKD, the therapeutic goal for hyperthyroid management changes. Allowing a slightly elevated T4 may preserve enough renal perfusion to keep the cat compensated. Fully normalizing thyroid hormone in a cat with Stage 2 CKD can precipitate Stage 3 within weeks.

Neither outcome is acceptable when the information to avoid both is available from a single pre-treatment panel.

What Standard Panels Miss

The standard pre-treatment workup for a hyperthyroid cat typically includes a CBC, chemistry panel with creatinine, T4, and urinalysis. Creatinine does not rise until 75% of nephron function is lost. SDMA, as discussed elsewhere, does better but still has a 22% miss rate for Stage 1 in cats — and hyperthyroidism directly suppresses the SDMA signal by inflating the apparent GFR.

A cat with true Stage 2 CKD (GFR 25-40 mL/min/1.73m²) can have an SDMA of 13 µg/dL while hyperthyroid. That reads as normal. Post-treatment, the same cat may present with SDMA of 22 µg/dL within 60 days — a jump that looks like rapid progression but actually represents the GFR that was present all along.

Urinary Biomarkers of Tubular Injury

The markers that perform best for detecting pre-existing nephron damage in hyperthyroid cats are those that measure tubular injury rather than filtration rate. When nephrons are damaged, the tubular epithelium releases specific proteins that appear in urine before GFR has declined enough to raise SDMA or creatinine.

The most useful in our experience:

• Urinary NAG (N-acetyl-beta-D-glucosaminidase): A lysosomal enzyme released by injured proximal tubular cells. Elevation is detectable 6-12 months before SDMA rises in cats with early CKD. Critically, NAG is not affected by GFR-inflating hyperthyroidism — it measures cellular injury, not filtration.
• NGAL (neutrophil gelatinase-associated lipocalin): Originally validated as an early AKI marker, urinary NGAL also identifies chronic tubular stress in cats with early CKD. It has more analytical variability than NAG but provides a complementary signal.
• Urinary protein:creatinine ratio at timed collection: A UPC above 0.4 in a hyperthyroid cat without glomerulonephritis history warrants immediate renal investigation, even with normal SDMA.

A Practical Pre-Treatment Protocol

The protocol we recommend to partner clinics for any cat presenting with confirmed or suspected hyperthyroidism:

1. Run full chemistry including SDMA and cystatin-C before initiating treatment
2. Add urinary NAG and UPC from the same visit urine sample
3. If NAG is elevated or UPC >0.4, add urinary NGAL and sediment evaluation
4. Recheck chemistry and SDMA at 4 weeks and 12 weeks post-treatment initiation regardless of baseline results
5. For any cat with two or more markers suggesting early CKD, consider methimazole trial with planned T4 target of 2-3 µg/dL rather than full normalization

Step 5 is the most clinically nuanced. The goal in a cat with concurrent Stage 1-2 CKD is not always to normalize thyroid function entirely — it is to reach the T4 level at which the cat maintains the best combined renal and cardiac function. This requires serial monitoring and individual titration, not a fixed-dose protocol.

What Our Model Adds

The challenge with multi-marker pre-treatment assessment is interpretation. Five values from different assays, each with breed and age-dependent reference ranges, are difficult to integrate clinically in a 15-minute appointment. Our platform generates a single renal risk score for hyperthyroid cats that incorporates all available markers and weights them against the cat's age, body condition score, and breed.

The output is not a diagnosis — it is a risk stratification: low, moderate, or high risk of concurrent CKD. Low risk gets standard post-treatment recheck at 4 weeks. Moderate risk gets the 4-week and 12-week protocol with tighter T4 targets. High risk triggers an explicit recommendation for nephrology consultation before methimazole initiation.

Of 214 hyperthyroid cats assessed with this workflow over 18 months, 7 received a high-risk classification. All 7 were confirmed to have CKD within 90 days — either at baseline upon nephrology workup, or immediately post-treatment. None were clinical surprises to the clinician who had the pre-treatment data.

Surprises are avoidable. The information has been in the blood sample all along.